Amgen Expects Stable Aranesp Pricing Despite J&J Lawsuit Over Rebates
Executive Summary
Amgen anticipates pricing for its anemia therapy Aranesp (darbepoetin) to be stable regardless of the outcome of a lawsuit by Johnson & Johnson challenging its discounting practices
You may also be interested in...
Amgen’s Bundling Of ESAs With Neulasta and Neupogen Draws House Scrutiny
Amgen's offering of discounts to physicians and clinics for purchasing the white blood cell growth factors Neulasta and Neupogen together with the erythropoiesis-stimulation agents Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) has once again come under scrutiny, this time from the House Energy and Commerce Committee
Amgen’s Bundling Of ESAs With Neulasta and Neupogen Draws House Scrutiny
Amgen's offering of discounts to physicians and clinics for purchasing the white blood cell growth factors Neulasta and Neupogen together with the erythropoiesis-stimulation agents Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) has once again come under scrutiny, this time from the House Energy and Commerce Committee
J&J/Amgen Bundling Dispute Could Lead To Stricter CMS Accounting Rules
Johnson & Johnson is moving on several fronts to counter Amgen pricing and discount policies it alleges are anti-competitive, and one result could be the Centers for Medicare & Medicaid Services (CMS) requiring more detailed discount reporting in the Medicare arena